Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts
Keywords: مرتد; Bevacizumab; Xenograft; Breast cancer; Transcriptomics; Metabolomics; PFS; Progression Free Survival; OS; Overall Survival; FDA; Food and Drug Administration; tCHO; total Choline; MRS; Magnetic Resonance Spectroscopy; PCho; Phosphocholine; GPC; Glyceropho